ba0001pp349 | Osteoporosis: pathophysiology and epidemiology | ECTS2013
Ronn Sofie
, Hald Jannie D
, Thisted Marianne
, Andersen Louise
, Gronhoj Louise
, Jensen Anders Bonde
, Langdahl Bente L
Introduction: Aromatase inhibitors (AI) used as adjuvant treatment of hormone-sensitive breast cancer reduce the level of circulating estrogen and cause accelerated bone loss. The aim of this study is to investigate the prevalence of osteoporosis in women with breast cancer and the effect of chemotherapy on the risk of osteoporosis.Methods: Three hundred and sixty women with hormone-sensitive breast cancer who were scheduled to start treatment with AI we...